Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 9/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | GPR3 | P46089 | 1/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | SCN1A | P35498 | 1/20 | 0.34 |
| ▸ | SCN4A | P35499 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18033877 | 0.88 | CYP2C9 (0.40) | CYP2C9MEN1NPC1CYP1A2PKM | |
| SCHEMBL18031757 | 0.86 | NPC1 (0.40) | CYP2C9MEN1NPC1CYP1A2PKM | |
| SCHEMBL18031759 | 0.86 | MAPT (0.47) | CYP2C9MEN1NPC1CYP1A2PKM | |
| SCHEMBL30574510 | 0.84 | THRB (0.46) | CYP2C9MEN1NPC1CYP1A2PKM | |
| SCHEMBL21294292 | 0.84 | THRB (0.46) | CYP2C9MEN1NPC1CYP1A2PKM | |
| SCHEMBL16664856 | 0.84 | RAB9A (0.37) | CYP2C9MEN1NPC1CYP1A2PKM | |
| SCHEMBL17995994 | 0.84 | MAOA (0.41) | CYP2C9MEN1NPC1CYP1A2PKM | |
| SCHEMBL21294291 | 0.82 | MAPT (0.38) | CYP2C9MEN1NPC1CYP1A2PKM | |
| SCHEMBL30574484 | 0.82 | MAPT (0.38) | CYP2C9MEN1NPC1CYP1A2PKM | |
| SCHEMBL16664852 | 0.82 | ABL1 (0.44) | CYP2C9MEN1NPC1CYP1A2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346586-A1 | CHROMENE DERIVATIVES AS INHIBITORS OF TCR-NCK INTERACTION | ARTAX BIOPHARMA INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-12319675-B2 | Chromene derivatives as inhibitors of TCR-Nck interaction | ARTAX BIOPHARMA INC. (US) | 2025-06-03 | — | — | US | disclosed |
| US-20240199592-A1 | CHROMENE DERIVATIVES AS INHIBITORS OF TCR-NCK INTERACTION | ARTAX BIOPHARMA INC. | 2024-06-20 | — | — | US | disclosed |
| CN-117304157-A | Chromene derivatives as inhibitors of TCR-NCK interactions | 阿塔克斯生物制药有限公司 | 2023-12-29 | — | — | CN | disclosed |
| US-11807633-B2 | Chromene derivatives as inhibitors of TCR-Nck interaction | ARTAX BIOPHARMA INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807633-B2 | Chromene derivatives as inhibitors of TCR-Nck interaction | ARTAX BIOPHARMA INC. (US) | 2023-11-07 | — | — | US | disclosed |
| CN-112189009-B | Chromene derivatives as inhibitors of TCR-NCK interactions | 阿塔克斯生物制药有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-20220081429-A1 | CHROMENE DERIVATIVES AS INHIBITORS OF TCR-NCK INTERACTION | ARTAX BIOPHARMA INC. | 2022-03-17 | — | — | US | disclosed |
| US-11008310-B2 | Chromene derivatives as inhibitors of TCR-Nck interaction | ARTAX BIOPHARMA INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-11008310-B2 | Chromene derivatives as inhibitors of TCR-Nck interaction | ARTAX BIOPHARMA INC. (US) | 2021-05-18 | — | — | US | disclosed |
| CN-112189009-A | Chromene derivatives as inhibitors of TCR-NCK interaction | 阿塔克斯生物制药有限公司 | 2021-01-05 | — | — | CN | disclosed |
| US-20200347042-A1 | CHROMENE DERIVATIVES AS INHIBITORS OF TCR-NCK INTERACTION | ARTAX BIOPHARMA INC. | 2020-11-05 | — | — | US | disclosed |
| US-20200347042-A1 | CHROMENE DERIVATIVES AS INHIBITORS OF TCR-NCK INTERACTION | ARTAX BIOPHARMA INC. | 2020-11-05 | — | — | US | disclosed |
| US-10696663-B2 | Chromene derivatives as inhibitors of TCR-NCK interaction | ARTAX BIOPHARMA INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-10696663-B2 | Chromene derivatives as inhibitors of TCR-NCK interaction | ARTAX BIOPHARMA INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190263792-A1 | CHROMENE DERIVATIVES AS INHIBITORS OF TCR-NCK INTERACTION | ARTAX BIOPHARMA INC. | 2019-08-29 | — | — | US | disclosed |
| US-20190263792-A1 | CHROMENE DERIVATIVES AS INHIBITORS OF TCR-NCK INTERACTION | ARTAX BIOPHARMA INC. | 2019-08-29 | — | — | US | disclosed |
| US-20160244423-A1 | CHROMENE DERIVATIVES SUBSTITUTED BY ALKOXIDE AS INHIBITORS OF THE TCR-NCK INTERACTION | ARTAX BIOPHARMA INC. (US) | 2016-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12319675-B2 | Chromene derivatives as inhibitors of TCR-Nck interaction | NCK1, NCKAP1, NCKAP1L | CYP2C9 3939/4885MEN1 4177/4885NPC1 1541/4885 |
| US-20240199592-A1 | CHROMENE DERIVATIVES AS INHIBITORS OF TCR-NCK INTERACTION | NCK1, NCKAP1, NCKAP1L | CYP2C9 3939/4885MEN1 4177/4885NPC1 1541/4885 |
| US-20220081429-A1 | CHROMENE DERIVATIVES AS INHIBITORS OF TCR-NCK INTERACTION | NCK1, NCKAP1, NCKAP1L | CYP2C9 3939/4885MEN1 4177/4885NPC1 1541/4885 |
| US-10696663-B2 | Chromene derivatives as inhibitors of TCR-NCK interaction | NCK1, NCKAP1, NCKAP1L | CYP2C9 3939/4885MEN1 4177/4885NPC1 1541/4885 |
| US-11807633-B2 | Chromene derivatives as inhibitors of TCR-Nck interaction | NCK1, NCKAP1, NCKAP1L | CYP2C9 3939/4885MEN1 4177/4885NPC1 1541/4885 |
| US-20160244423-A1 | CHROMENE DERIVATIVES SUBSTITUTED BY ALKOXIDE AS INHIBITORS OF THE TCR-NCK INTERACTION | NFATC1, NCKAP1, NCK1 | CYP2C9 2022/4885MEN1 4392/4885NPC1 2020/4885 |
| US-20200347042-A1 | CHROMENE DERIVATIVES AS INHIBITORS OF TCR-NCK INTERACTION | NCK1, NCKAP1, NCKAP1L | CYP2C9 3939/4885MEN1 4177/4885NPC1 1541/4885 |
| US-20250346586-A1 | CHROMENE DERIVATIVES AS INHIBITORS OF TCR-NCK INTERACTION | NCK1, NCKAP1, NCKAP1L | CYP2C9 3939/4885MEN1 4177/4885NPC1 1541/4885 |
| US-20190263792-A1 | CHROMENE DERIVATIVES AS INHIBITORS OF TCR-NCK INTERACTION | NCK1, NCKAP1, NCKAP1L | CYP2C9 3939/4885MEN1 4177/4885NPC1 1541/4885 |
| US-11008310-B2 | Chromene derivatives as inhibitors of TCR-Nck interaction | NCK1, NCKAP1, NCKAP1L | CYP2C9 3939/4885MEN1 4177/4885NPC1 1541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.